1B6K image
Deposition Date 1999-01-17
Release Date 2000-01-07
Last Version Date 2023-11-15
Entry Detail
PDB ID:
1B6K
Title:
HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 5
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
1.85 Å
R-Value Free:
0.23
R-Value Work:
0.20
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:RETROPEPSIN
Gene (Uniprot):gag-pol
Mutations:GLN7LYS, LEU33ILE, CYS67ABA, CYS95ABA, GLN107LYS, LEU133ILE, CYS167ABA, CYS195ABA
Chain IDs:A, B
Chain Length:99
Number of Molecules:2
Biological Source:Human immunodeficiency virus 1
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
ABA A ALA ALPHA-AMINOBUTYRIC ACID
Primary Citation
Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.
Biochemistry 38 7978 7988 (1999)
PMID: 10387041 DOI: 10.1021/bi990174x

Abstact

High-resolution crystal structures are described for seven macrocycles complexed with HIV-1 protease (HIVPR). The macrocycles possess two amides and an aromatic group within 15-17 membered rings designed to replace N- or C-terminal tripeptides from peptidic inhibitors of HIVPR. Appended to each macrocycle is a transition state isostere and either an acyclic peptide, nonpeptide, or another macrocycle. These cyclic analogues are potent inhibitors of HIVPR, and the crystal structures show them to be structural mimics of acyclic peptides, binding in the active site of HIVPR via the same interactions. Each macrocycle is restrained to adopt a beta-strand conformation which is preorganized for protease binding. An unusual feature of the binding of C-terminal macrocyclic inhibitors is the interaction between a positively charged secondary amine and a catalytic aspartate of HIVPR. A bicyclic inhibitor binds similarly through its secondary amine that lies between its component N-terminal and C-terminal macrocycles. In contrast, the corresponding tertiary amine of the N-terminal macrocycles does not interact with the catalytic aspartates. The amine-aspartate interaction induces a 1.5 A N-terminal translation of the inhibitors in the active site and is accompanied by weakened interactions with a water molecule that bridges the ligand to the enzyme, as well as static disorder in enzyme flap residues. This flexibility may facilitate peptide cleavage and product dissociation during catalysis. Proteases [Aba67,95]HIVPR and [Lys7,Ile33,Aba67,95]HIVPR used in this work were shown to have very similar crystal structures.

Legend

Protein

Chemical

Disease

Primary Citation of related structures